1
|
Papadakis GE, de Kalbermatten B, Dormoy A, Salenave S, Trabado S, Vieira-Pinto O, Richa C, Kamenicky P, Chanson P, Maione L, Pitteloud N, Young J. Impact of Cushing's syndrome on the gonadotrope axis and testicular functions in men. Hum Reprod 2023; 38:2350-2361. [PMID: 37742130 DOI: 10.1093/humrep/dead187] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2023] [Revised: 08/17/2023] [Indexed: 09/25/2023] Open
Abstract
STUDY QUESTION Does Cushing's syndrome (CS) differently affect the gonadotrope axis and testicular functions (GA/TF) according to the hypercortisolism intensity and underlying etiology? SUMMARY ANSWER Endogenous cortisol excess caused by CS leads to varying degrees of hypogonadotropic hypogonadism (HH) with more severe GA/TF impairment and altered spermatogenesis in men with intense hypercortisolism associated with paraneoplastic/ectopic adrenocorticotrophic hormone (ACTH) secretion (EAS). WHAT IS KNOWN ALREADY CS is very rarely studied in men due to its lower prevalence in men than in women. In a few old reports focusing exclusively on a limited number of men with Cushing's disease (CD), the occurrence of hypogonadism was reported. However, a detailed assessment of the impact of CS on the GA/TF in a significant series of patients has not been performed. Yet, hypogonadism could worsen CS-associated comorbidities such as osteoporosis and myopathy. To date, the full spectrum of GA/TF impairment in men with CS of different etiologies and intensity remains unknown. STUDY DESIGN, SIZE, DURATION In this monocentric study, 89 men with CS diagnosed at a tertiary endocrine university center (Bicêtre, Paris Saclay) between January 1990 and July 2021 were evaluated and compared to 40 normal men of similar age. PARTICIPANTS/MATERIALS, SETTING, METHODS The CS patient cohort of 89 men included 51 with CD, 29 with EAS and 9 with CS of adrenal origin i.e. (ACTH-independent CS (AI-CS)). They all had frank hypercortisolism, with increased 24 h-urinary-free cortisol (24 h-UFC) in two separate samples. A case-control study was performed focusing on pituitary gonadotrope function and testicular sex steroids and peptides. An additional set of six CS men had an evaluation including semen analysis. In a subgroup of 20 men with available data after CS remission, a longitudinal analysis was conducted to assess the reversibility of GA/TF defects. MAIN RESULTS AND THE ROLE OF CHANCE Compared to controls, men with CS had significantly lower total testosterone (TT), bioavailable TT, and free TT (P < 0.0001). Hypogonadism, defined as serum TT levels <3.0 ng/ml, was present in 83% of men with EAS, in 61% of men with CD, and in 33% of men with AI-CS. Low-normal LH concentrations in the included men with hypercortisolism indicated HH. Serum sex hormone-binding globulin levels were moderately decreased in men with CD (P = 0.01 vs controls). Among the CS men, those with EAS had significantly lower TT, LH, and FSH levels than those with CD or AI-CS. When compared to controls, patients with EAS were the only group exhibiting a significant decrease in both serum FSH (P = 0.002) and the testicular peptides inhibin B (P < 0.0001) and anti-Müllerian hormone (P = 0.003). Serum INSL3 levels were significantly lower in men with CD than in the controls (P = 0.03). Of note, 24 h-UFC and ACTH were inversely and significantly associated with the majority of reproductive hormones including LH, FSH, TT, and inhibin B. Following successful curative therapy, reproductive assessment at a mean of 6.0 ± 4.3 years showed a significant increase in serum TT (P < 0.0001) and plasma LH (P = 0.02) levels, indicating a reversal of HH in 75% of the affected males. Among the six patients with available semen analysis, the two EAS cases exhibited a decrease in Sertoli cell peptides associated with a severe oligozoospermia, which completely normalized following removal of the source of hypercortisolism. LIMITATIONS, REASONS FOR CAUTION The potential bias due to the retrospective design is counteracted by the analysis of the largest male CS cohort to date as well as the use of stringent inclusion and exclusion criteria. Due to the low number of patients with semen analysis in this study, further research is needed to unravel the full spectrum of spermatogenesis defects in men with CS. WIDER IMPLICATIONS OF THE FINDINGS This work reveals the variable spectrum of reproductive impact in men with CS. We demonstrate that GA/TF impairment depends on the intensity of hypercortisolism which in turn is related to the underlying etiology. The causal link between hypercortisolism and GA/TF impairment was attested by its reversibility in most patients after CS remission. The wider implications of our findings lie in the potential generalization to a much commoner entity, iatrogenic CS due to chronic exposure to exogenous glucocorticoids. STUDY FUNDING/COMPETING INTEREST(S) Several research grants were attributed to J.Y.: (i) a grant from Programme Hospitalier de Recherche Clinique (PHRC # P081212 HYPOPROTEO); (ii) a grant from the French Association of Patients with Adrenal Diseases ('Association surrénales'); and (iii) independent Investigator Research Grants from HRA Pharma, Novartis and Recordati Pharma. A SICPA Foundation grant (Lausanne, Switzerland) allowed protected research time for G.E.P. The above sponsors were not involved in any part of the study. The authors have no competing or other conflicts of interest to declare. TRIAL REGISTRATION NUMBER N/A.
Collapse
Affiliation(s)
- Georgios E Papadakis
- Service of Endocrinology, Diabetes and Metabolism, Lausanne University Hospital, Lausanne, Switzerland
- Paris-Saclay University; Assistance Publique-Hôpitaux de Paris, Department of Reproductive Endocrinology, Reference Center for Rare Pituitary Diseases HYPO, Bicêtre Hospital, Le Kremlin-Bicêtre, France
- Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland
| | - Benedicte de Kalbermatten
- Paris-Saclay University; Assistance Publique-Hôpitaux de Paris, Department of Reproductive Endocrinology, Reference Center for Rare Pituitary Diseases HYPO, Bicêtre Hospital, Le Kremlin-Bicêtre, France
| | - Alexandre Dormoy
- Paris-Saclay University; Assistance Publique-Hôpitaux de Paris, Department of Reproductive Endocrinology, Reference Center for Rare Pituitary Diseases HYPO, Bicêtre Hospital, Le Kremlin-Bicêtre, France
| | - Sylvie Salenave
- Paris-Saclay University; Assistance Publique-Hôpitaux de Paris, Department of Reproductive Endocrinology, Reference Center for Rare Pituitary Diseases HYPO, Bicêtre Hospital, Le Kremlin-Bicêtre, France
| | - Severine Trabado
- Service de Génétique Moléculaire, Pharmacogénétique et Hormonologie, Hôpitaux Universitaires Paris Saclay, Assistance Publique-Hôpitaux de Paris, CHU Bicêtre, L Kremlin Bicêtre, France
| | - Oceana Vieira-Pinto
- Paris-Saclay University; Assistance Publique-Hôpitaux de Paris, Department of Reproductive Endocrinology, Reference Center for Rare Pituitary Diseases HYPO, Bicêtre Hospital, Le Kremlin-Bicêtre, France
| | - Carine Richa
- Paris-Saclay University; Assistance Publique-Hôpitaux de Paris, Department of Reproductive Endocrinology, Reference Center for Rare Pituitary Diseases HYPO, Bicêtre Hospital, Le Kremlin-Bicêtre, France
| | - Peter Kamenicky
- Paris-Saclay University; Assistance Publique-Hôpitaux de Paris, Department of Reproductive Endocrinology, Reference Center for Rare Pituitary Diseases HYPO, Bicêtre Hospital, Le Kremlin-Bicêtre, France
- INSERM UMR_S 1185, Paris-Saclay Medical School, Le Kremlin-Bicêtre, France
- University Paris Saclay, Orsay, France
| | - Philippe Chanson
- Paris-Saclay University; Assistance Publique-Hôpitaux de Paris, Department of Reproductive Endocrinology, Reference Center for Rare Pituitary Diseases HYPO, Bicêtre Hospital, Le Kremlin-Bicêtre, France
- INSERM UMR_S 1185, Paris-Saclay Medical School, Le Kremlin-Bicêtre, France
- University Paris Saclay, Orsay, France
| | - Luigi Maione
- Paris-Saclay University; Assistance Publique-Hôpitaux de Paris, Department of Reproductive Endocrinology, Reference Center for Rare Pituitary Diseases HYPO, Bicêtre Hospital, Le Kremlin-Bicêtre, France
- INSERM UMR_S 1185, Paris-Saclay Medical School, Le Kremlin-Bicêtre, France
- University Paris Saclay, Orsay, France
| | - Nelly Pitteloud
- Service of Endocrinology, Diabetes and Metabolism, Lausanne University Hospital, Lausanne, Switzerland
- Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland
| | - Jacques Young
- Paris-Saclay University; Assistance Publique-Hôpitaux de Paris, Department of Reproductive Endocrinology, Reference Center for Rare Pituitary Diseases HYPO, Bicêtre Hospital, Le Kremlin-Bicêtre, France
- INSERM UMR_S 1185, Paris-Saclay Medical School, Le Kremlin-Bicêtre, France
- University Paris Saclay, Orsay, France
| |
Collapse
|
2
|
Wolf P, Bouazizi K, Kachenoura N, Piedvache C, Gallo A, Salenave S, Maione L, Young J, Prigent M, Lecoq AL, Kuhn E, Agostini H, Trabado S, Redheuil A, Chanson P, Kamenický P. Increase in intracellular and extracellular myocardial mass in patients with acromegaly: a cardiac magnetic resonance imaging study. Eur J Endocrinol 2023; 189:199-207. [PMID: 37549351 DOI: 10.1093/ejendo/lvad105] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/30/2023] [Revised: 07/10/2023] [Accepted: 07/18/2023] [Indexed: 08/09/2023]
Abstract
BACKGROUND Acromegaly is associated with an increased left ventricular (LV) mass, as reported in echo-based and, more recently, in a few cardiac magnetic resonance imaging (MRI) studies. One possible explanation for this increased LV mass could be water retention and subsequent myocardial edema. METHODS In this prospective cross-sectional study, 26 patients with active acromegaly before and after treatment and 31 controls of comparable age and sex were investigated using cardiac MRI. Cardiac morphology, function, and myocardial tissue characteristics were evaluated. Myocardial T2 relaxation time was used as the main outcome measure of myocardial edema. The study was registered with clinicaltrials.gov (NCT02948322). RESULTS Patients compared to controls had greater LV mass indexes (58.1 [54.7-68.6] vs 46.0 [41.3-49.8] g/m2; P < .001) and end-diastolic volume (EDV) indexes (97.3 [88-101.2] vs 81.6 [78.1-96.2] mL/m2; P = .0069) and had comparable global contractile function. T2 values were not different between patients and controls. Both intracellular (43.83 [41.0-50.0] vs 34.32 [28.9-38.7] g/m2; P < .001) and extracellular (15.06 [13.5-17.1] vs 11.6 [10.8-12.7] g/m2; P < .001) LV mass indexes were higher in patients compared to controls. Log growth hormone correlated with myocardial mass (r = 0.75; P < .001). Sex, systolic blood pressure (BP), and the presence of acromegaly were predictors of the LV mass index. The extracellular LV mass index was associated with sex and the presence of acromegaly, whereas the intracellular LV mass index was associated with sex, systolic BP, and high-density lipoprotein (HDL) cholesterol. Acromegaly treatment reduced EDV and total and intracellular LV mass indexes without significantly affecting extracellular mass. CONCLUSION Acromegaly results in a disease-specific form of LV hypertrophic remodeling, characterized by an increase in both intra- and extracellular mass. The LV mass index and intracellular mass were decreased by treatment.
Collapse
Affiliation(s)
- Peter Wolf
- Université Paris-Saclay, Inserm, Physiologie et Physiopathologie Endocriniennes, AP-HP, Hôpital Bicêtre, Service d'Endocrinologie et des Maladies de la Reproduction, Centre de Référence des Maladies Rares de l'Hypophyse, 94275 Le Kremlin-Bicêtre, France
- Division of Endocrinology and Metabolism, Department of Internal Medicine III, Medical University of Vienna, 1090 Vienna, Austria
| | - Khaoula Bouazizi
- CNRS, Inserm, Laboratoire d'Imagerie Biomédicale, LIB, Sorbonne Université, 75006 Paris, France
- Institut de Cardiométabolisme et Nutrition (ICAN), 75013 Paris, France
| | - Nadjia Kachenoura
- CNRS, Inserm, Laboratoire d'Imagerie Biomédicale, LIB, Sorbonne Université, 75006 Paris, France
- Institut de Cardiométabolisme et Nutrition (ICAN), 75013 Paris, France
| | - Céline Piedvache
- AP-HP, Hôpital Bicêtre, Unité de Recherche Clinique, 94275 Le Kremlin-Bicêtre, France
| | - Antonio Gallo
- Sorbonne Université, Inserm, Unité de recherche sur les maladies cardiovasculaires et métaboliques, AP-HP, Hôpital Pitié-Salpètriêre, Service de Nutrition, 75013 Paris, France
| | - Sylvie Salenave
- Université Paris-Saclay, Inserm, Physiologie et Physiopathologie Endocriniennes, AP-HP, Hôpital Bicêtre, Service d'Endocrinologie et des Maladies de la Reproduction, Centre de Référence des Maladies Rares de l'Hypophyse, 94275 Le Kremlin-Bicêtre, France
| | - Luigi Maione
- Université Paris-Saclay, Inserm, Physiologie et Physiopathologie Endocriniennes, AP-HP, Hôpital Bicêtre, Service d'Endocrinologie et des Maladies de la Reproduction, Centre de Référence des Maladies Rares de l'Hypophyse, 94275 Le Kremlin-Bicêtre, France
| | - Jacques Young
- Université Paris-Saclay, Inserm, Physiologie et Physiopathologie Endocriniennes, AP-HP, Hôpital Bicêtre, Service d'Endocrinologie et des Maladies de la Reproduction, Centre de Référence des Maladies Rares de l'Hypophyse, 94275 Le Kremlin-Bicêtre, France
| | - Mikaël Prigent
- Institut de Cardiométabolisme et Nutrition (ICAN), 75013 Paris, France
| | - Anne-Lise Lecoq
- Université Paris-Saclay, Inserm, Physiologie et Physiopathologie Endocriniennes, AP-HP, Hôpital Bicêtre, Service d'Endocrinologie et des Maladies de la Reproduction, Centre de Référence des Maladies Rares de l'Hypophyse, 94275 Le Kremlin-Bicêtre, France
| | - Emmanuelle Kuhn
- Université Paris-Saclay, Inserm, Physiologie et Physiopathologie Endocriniennes, AP-HP, Hôpital Bicêtre, Service d'Endocrinologie et des Maladies de la Reproduction, Centre de Référence des Maladies Rares de l'Hypophyse, 94275 Le Kremlin-Bicêtre, France
| | - Helene Agostini
- AP-HP, Hôpital Bicêtre, Unité de Recherche Clinique, 94275 Le Kremlin-Bicêtre, France
| | - Severine Trabado
- Université Paris-Saclay, Inserm, Physiologie et Physiopathologie Endocriniennes, AP-HP, Hôpital Bicêtre, Service de Génétique Moléculaire, Pharmacogénétique et Hormonologie, 94275 Le Kremlin-Bicêtre, France
| | - Alban Redheuil
- CNRS, Inserm, Laboratoire d'Imagerie Biomédicale, LIB, Sorbonne Université, 75006 Paris, France
- Institut de Cardiométabolisme et Nutrition (ICAN), 75013 Paris, France
- AP-HP, Hôpital Pitié-Salpêtrière, Unité d'Imagerie Cardiovasculaire et Thoracique, 75013 Paris, France
| | - Philippe Chanson
- Université Paris-Saclay, Inserm, Physiologie et Physiopathologie Endocriniennes, AP-HP, Hôpital Bicêtre, Service d'Endocrinologie et des Maladies de la Reproduction, Centre de Référence des Maladies Rares de l'Hypophyse, 94275 Le Kremlin-Bicêtre, France
| | - Peter Kamenický
- Université Paris-Saclay, Inserm, Physiologie et Physiopathologie Endocriniennes, AP-HP, Hôpital Bicêtre, Service d'Endocrinologie et des Maladies de la Reproduction, Centre de Référence des Maladies Rares de l'Hypophyse, 94275 Le Kremlin-Bicêtre, France
| |
Collapse
|
3
|
Bachelot G, Bachelot A, Bonnier M, Salem JE, Farabos D, Trabado S, Dupont C, Kamenicky P, Houang M, Fiet J, Le Bouc Y, Young J, Lamazière A. Combining metabolomics and machine learning models as a tool to distinguish non-classic 21-hydroxylase deficiency from polycystic ovary syndrome without adrenocorticotropic hormone testing. Hum Reprod 2023; 38:266-276. [PMID: 36427016 DOI: 10.1093/humrep/deac254] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2022] [Revised: 11/03/2022] [Indexed: 11/27/2022] Open
Abstract
STUDY QUESTION Can a combination of metabolomic signature and machine learning (ML) models distinguish nonclassic 21-hydroxylase deficiency (NC21OHD) from polycystic ovary syndrome (PCOS) without adrenocorticotrophic hormone (ACTH) testing? SUMMARY ANSWER A single sampling methodology may be an alternative to the dynamic ACTH test in order to exclude the diagnosis of NC21OHD in the presence of a clinical hyperandrogenic presentation at any time of the menstrual cycle. WHAT IS KNOWN ALREADY The clinical presentation of patients with NC21OHD is similar with that for other disorders of androgen excess. Currently, cosyntropin stimulation remains the gold standard diagnosis of NC21OHD. STUDY DESIGN, SIZE, DURATION The study was designed using a bicentric recruitment: an internal training set included 19 women with NC21OHD and 19 controls used for developing the model; a test set included 17 NC21OHD, 72 controls and 266 PCOS patients used to evaluate the performance of the diagnostic strategy thanks to an ML approach. PARTICIPANTS/MATERIALS, SETTING, METHODS Fifteen steroid species were measured in serum by liquid chromatography-mass spectrometry (LC-MS/MS). This set of 15 steroids (defined as 'steroidome') used to map the steroid biosynthesis pathway was the input for our models. MAIN RESULTS AND THE ROLE OF CHANCE From a single sample, modeling involving metabolic pathway mapping by profiling 15 circulating steroids allowed us to identify perfectly NC21OHD from a confounding PCOS population. The constructed model using baseline LC-MS/MS-acquired steroid fingerprinting successfully excluded all 17 NC21OHDs (sensitivity and specificity of 100%) from 266 PCOS from an external testing cohort of originally 549 women, without the use of ACTH testing. Blood sampling timing during the menstrual cycle phase did not impact the efficiency of our model. LIMITATIONS, REASONS FOR CAUTION The main limitations were the use of a restricted and fully prospective cohort as well as an analytical issue, as not all laboratories are equipped with mass spectrometers able to routinely measure this panel of 15 steroids. Moreover, the robustness of our model needs to be established with a larger prospective study for definitive validation in clinical practice. WIDER IMPLICATIONS OF THE FINDINGS This tool makes it possible to propose a new semiology for the management of hyperandrogenism. The model presents better diagnostic performances compared to the current reference strategy. The management of patients may be facilitated by limiting the use of ACTH tests. Finally, the modeling process allows a classification of steroid contributions to rationalize the biomarker approach and highlight some underlying pathophysiological mechanisms. STUDY FUNDING/COMPETING INTEREST(S) This study was supported by 'Agence Française de Lutte contre le dopage' and DIM Région Ile de France. This study was supported by the French institutional PHRC 2010-AOR10032 funding source and APHP. All authors declare no competing financial interests. TRIAL REGISTRATION NUMBER N/A.
Collapse
Affiliation(s)
- Guillaume Bachelot
- Service de Biologie de La Reproduction-CECOS, Hôpital Tenon, AP-HP.Sorbonne Université, Paris, France.,Sorbonne Université, Saint Antoine Research Center, INSERM UMR 938, Paris, France.,Département de Métabolomique Clinique, Hôpital Saint Antoine, AP-HP.Sorbonne Université, Paris, France
| | - Anne Bachelot
- Service d'Endocrinologie et Médecine de La Reproduction, Centre de Référence Des Maladies Endocriniennes Rares de La Croissance et du Développement, Centre Des Pathologies Gynécologiques Rares, Hôpital Pitié Salpêtrière (APHP), Sorbonne Université, Paris, France
| | - Marion Bonnier
- Service d'Endocrinologie et Médecine de La Reproduction, Centre de Référence Des Maladies Endocriniennes Rares de La Croissance et du Développement, Centre Des Pathologies Gynécologiques Rares, Hôpital Pitié Salpêtrière (APHP), Sorbonne Université, Paris, France
| | - Joe-Elie Salem
- CIC-1901 and Department of Pharmacology, Pitié-Salpêtrière Hospital, AP-HP, Sorbonne Université, Inserm, Paris, France
| | - Dominique Farabos
- Sorbonne Université, Saint Antoine Research Center, INSERM UMR 938, Paris, France
| | - Severine Trabado
- Service de Génétique Moléculaire, Pharmacogénétique et Hormonologie, Assistance Publique-Hôpitaux de Paris, Bicêtre Hospital, Le Kremlin-Bicêtre, France.,INSERM UMR-U1185, Paris-Saclay University, Le Kremlin-Bicêtre, France
| | - Charlotte Dupont
- Service de Biologie de La Reproduction-CECOS, Hôpital Tenon, AP-HP.Sorbonne Université, Paris, France.,Sorbonne Université, Saint Antoine Research Center, INSERM UMR 938, Paris, France
| | - Peter Kamenicky
- INSERM UMR-U1185, Paris-Saclay University, Le Kremlin-Bicêtre, France.,University Paris-Saclay, Orsay, France.,Department of Reproductive Endocrinology, Assistance Publique-Hôpitaux de Paris, Bicêtre Hospital, Le Kremlin-Bicêtre, France
| | - Muriel Houang
- Sorbonne Université, Saint Antoine Research Center, INSERM UMR 938, Paris, France.,Explorations Fonctionnelles Endocriniennes, Hôpital Armand Trousseau, AP-HP, Paris, France
| | - Jean Fiet
- Sorbonne Université, Saint Antoine Research Center, INSERM UMR 938, Paris, France.,Département de Métabolomique Clinique, Hôpital Saint Antoine, AP-HP.Sorbonne Université, Paris, France
| | - Yves Le Bouc
- Sorbonne Université, Saint Antoine Research Center, INSERM UMR 938, Paris, France.,Explorations Fonctionnelles Endocriniennes, Hôpital Armand Trousseau, AP-HP, Paris, France
| | - Jacques Young
- INSERM UMR-U1185, Paris-Saclay University, Le Kremlin-Bicêtre, France.,University Paris-Saclay, Orsay, France.,Department of Reproductive Endocrinology, Assistance Publique-Hôpitaux de Paris, Bicêtre Hospital, Le Kremlin-Bicêtre, France
| | - Antonin Lamazière
- Sorbonne Université, Saint Antoine Research Center, INSERM UMR 938, Paris, France.,Département de Métabolomique Clinique, Hôpital Saint Antoine, AP-HP.Sorbonne Université, Paris, France
| |
Collapse
|
4
|
El Asmar K, Annan NB, Khoury R, Colle R, Martin S, Ghoul TE, Trabado S, Chanson P, Feve B, Verstuyft C, Becquemont L, Corruble E. Non-overweight depressed patients who respond to antidepressant treatment have a higher risk of later metabolic syndrome: findings from the METADAP cohort. Psychol Med 2023; 53:1-10. [PMID: 36628576 PMCID: PMC10600935 DOI: 10.1017/s0033291722003919] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/10/2022] [Revised: 11/08/2022] [Accepted: 12/12/2022] [Indexed: 01/12/2023]
Abstract
BACKGROUND Major depressive disorder (MDD) is a complex disorder with a significant public health burden. Depression remission is often associated with weight gain, a major risk factor for metabolic syndrome (MetS). The primary objective of our study was to assess prospectively the impact of response to antidepressant treatment on developing MetS in a sample of MDD patients with a current major depressive episode (MDE) and who are newly initiating their treatment. METHODS In the 6-month prospective METADAP cohort, non-overweight patients, body mass index <25 kg/m2, with MDD and a current MDE were assessed for treatment response after 3 months of treatment, and incidence of MetS after 3 and 6 months of treatment. Outcome variables were MetS, number of MetS criteria, and each MetS criterion (high waist circumference, high blood pressure, high triglyceridemia, low high-density lipoprotein-cholesterolemia, and high fasting plasma glucose). RESULTS In total, 98/169 patients (58%) responded to treatment after 3 months. A total of 2.7% (1/38) developed MetS out of which 12.7% (10/79) (p value < 0.001) had responded to treatment after 3 months. The fixed-effect regression models showed that those who responded to treatment after 3 months of follow-up had an 8.6 times higher odds of developing MetS (odds ratio = 8.58, 95% confidence interval 3.89-18.93, p value < 0.001). CONCLUSION Compared to non-responders, non-overweight patients who responded to treatment after 3 months of antidepressant treatment had a significantly higher risk of developing MetS during the 6 months of treatment. Psychiatrists and nurses should closely monitor the metabolic profile of their patients, especially those who respond to treatment.
Collapse
Affiliation(s)
- K. El Asmar
- CESP, MOODS Team, INSERM UMR 1018, Faculté de Médecine, Univ. Paris-Saclay, Le Kremlin Bicêtre F-94275, France
- Department of Epidemiology and Population Health, Faculty of Health Sciences, American University of Beirut, Beirut, Lebanon
| | - N. B. Annan
- Department of Epidemiology and Population Health, Faculty of Health Sciences, American University of Beirut, Beirut, Lebanon
| | - R. Khoury
- Department of Epidemiology and Population Health, Faculty of Health Sciences, American University of Beirut, Beirut, Lebanon
| | - R. Colle
- CESP, MOODS Team, INSERM UMR 1018, Faculté de Médecine, Univ. Paris-Saclay, Le Kremlin Bicêtre F-94275, France
- Service Hospitalo-Universitaire de Psychiatrie de Bicêtre, Hôpitaux Universitaires Paris-Saclay, Assistance Publique Hôpitaux de Paris, Hôpital de Bicêtre, Le Kremlin Bicêtre F-94275, France
| | - S. Martin
- CESP, MOODS Team, INSERM UMR 1018, Faculté de Médecine, Univ. Paris-Saclay, Le Kremlin Bicêtre F-94275, France
- Service Hospitalo-Universitaire de Psychiatrie de Bicêtre, Hôpitaux Universitaires Paris-Saclay, Assistance Publique Hôpitaux de Paris, Hôpital de Bicêtre, Le Kremlin Bicêtre F-94275, France
| | - T. E. Ghoul
- Department of Epidemiology and Population Health, Faculty of Health Sciences, American University of Beirut, Beirut, Lebanon
| | - S. Trabado
- INSERM UMR-S U1185, Faculté de Médecine, Univ. Paris-Saclay, Le Kremlin Bicêtre F-94275, France
- Service de Génétique Moléculaire, Pharmacogénétique et Hormonologie de Bicêtre, Hôpitaux Universitaires Paris-Saclay, Assistance Publique-Hôpitaux de Paris, Hôpital de Bicêtre, Le Kremlin Bicêtre F-94275, France
| | - P. Chanson
- INSERM UMR-S U1185, Faculté de Médecine, Univ. Paris-Saclay, Le Kremlin Bicêtre F-94275, France
- Service d'Endocrinologie et des Maladies de la Reproduction, Centre de Référence des Maladies Rares de l'Hypophyse, Assistance Publique-Hôpitaux de Paris, Hôpital de Bicêtre, Le Kremlin Bicêtre F-94275, France
| | - B. Feve
- Sorbonne Université-INSERM, Centre de Recherche Saint-Antoine, Institut Hospitalo-Universitaire ICAN, Service d'Endocrinologie, Hôpital Saint-Antoine, Assistance Publique-Hôpitaux de Paris, Paris F-75012, France
| | - C. Verstuyft
- CESP, MOODS Team, INSERM UMR 1018, Faculté de Médecine, Univ. Paris-Saclay, Le Kremlin Bicêtre F-94275, France
- Service de Génétique Moléculaire, Pharmacogénétique et Hormonologie de Bicêtre, Hôpitaux Universitaires Paris-Saclay, Assistance Publique-Hôpitaux de Paris, Hôpital de Bicêtre, Le Kremlin Bicêtre F-94275, France
| | - L. Becquemont
- CESP, MOODS Team, INSERM UMR 1018, Faculté de Médecine, Univ. Paris-Saclay, Le Kremlin Bicêtre F-94275, France
- Centre de recherche clinique, Hôpitaux Universitaires Paris-Saclay, Assistance Publique-Hôpitaux de Paris, Hôpital de Bicêtre, Le Kremlin Bicêtre F-94275, France
| | - E. Corruble
- CESP, MOODS Team, INSERM UMR 1018, Faculté de Médecine, Univ. Paris-Saclay, Le Kremlin Bicêtre F-94275, France
- Service Hospitalo-Universitaire de Psychiatrie de Bicêtre, Hôpitaux Universitaires Paris-Saclay, Assistance Publique Hôpitaux de Paris, Hôpital de Bicêtre, Le Kremlin Bicêtre F-94275, France
| |
Collapse
|
5
|
Loeb E, El Asmar K, Trabado S, Gressier F, Colle R, Rigal A, Martin S, Verstuyft C, Fève B, Chanson P, Becquemont L, Corruble E. Nitric Oxide Synthase activity in major depressive episodes before and after antidepressant treatment: Results of a large case-control treatment study. Psychol Med 2022; 52:80-89. [PMID: 32524920 DOI: 10.1017/s0033291720001749] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
BACKGROUND Nitric oxide synthase (NOS) activity, an enzyme potentially involved in the major depressive episodes (MDE), could be indirectly measured by the L-Citrulline/L-Arginine ratio (L-Cit/L-Arg). The aim of this study was: (1) to compare the NOS activity of patients with a MDE to that of healthy controls (HC); (2) to assess its change after antidepressant treatment. METHODS A total of 460 patients with a current MDE in a context of major depressive disorder (MDD) were compared to 895 HC for NOS activity (L-Cit/L-Arg plasma ratio). L-Arg and L-Cit plasma levels were measured using a MS-based liquid chromatography method. Depressed patients were assessed at baseline, and after 3 and 6 months of antidepressant treatment for depression severity and clinical response. RESULTS Depressed patients had a lower NOS activity than HC at baseline [0.31 ± 0.09 v. 0.38 ± 0.12; 95% confidence interval (CI) -0.084 to -0.062, p < 0.0001]. Lower NOS activity at baseline predicted a higher response rate [odds ratio (OR) = 29.20; 95% CI 1.58-536.37; p = 0.023]. NOS activity in depressed patients increased significantly up to 0.34 ± 0.08 after antidepressant treatment (Est = 0.0034; 95% CI 0.0002-0.0067; p = 0.03). CONCLUSIONS Depressed patients have a decreased NOS activity that improves after antidepressant treatment and predicts drug response. NOS activity may be a promising biomarker for MDE in a context of MDD.
Collapse
Affiliation(s)
- E Loeb
- INSERM CESP - Equipe 'Moods'- Univ Paris-Saclay, 94275 Le Kremlin Bicêtre, France
- Service de Psychiatrie- Hôpital Bicêtre- GH Paris Saclay- APHP, 94275 Le Kremlin Bicêtre, France
- Faculté de Médecine Paris-Saclay, 94275 Le Kremlin Bicêtre, France
| | - K El Asmar
- INSERM CESP - Equipe 'Moods'- Univ Paris-Saclay, 94275 Le Kremlin Bicêtre, France
| | - S Trabado
- Faculté de Médecine Paris-Saclay, 94275 Le Kremlin Bicêtre, France
- Inserm U1185 - Univ Paris-Sud, 94275 Le Kremlin Bicêtre, France
- Service de Génétique moléculaire, Pharmacogénétique et Hormonologie- CHU de Bicêtre- APHP, 94275 Le Kremlin Bicêtre, France
| | - F Gressier
- INSERM CESP - Equipe 'Moods'- Univ Paris-Saclay, 94275 Le Kremlin Bicêtre, France
- Service de Psychiatrie- Hôpital Bicêtre- GH Paris Saclay- APHP, 94275 Le Kremlin Bicêtre, France
- Faculté de Médecine Paris-Saclay, 94275 Le Kremlin Bicêtre, France
| | - R Colle
- INSERM CESP - Equipe 'Moods'- Univ Paris-Saclay, 94275 Le Kremlin Bicêtre, France
- Service de Psychiatrie- Hôpital Bicêtre- GH Paris Saclay- APHP, 94275 Le Kremlin Bicêtre, France
- Faculté de Médecine Paris-Saclay, 94275 Le Kremlin Bicêtre, France
| | - A Rigal
- INSERM CESP - Equipe 'Moods'- Univ Paris-Saclay, 94275 Le Kremlin Bicêtre, France
- Service de Psychiatrie- Hôpital Bicêtre- GH Paris Saclay- APHP, 94275 Le Kremlin Bicêtre, France
- Faculté de Médecine Paris-Saclay, 94275 Le Kremlin Bicêtre, France
| | - S Martin
- INSERM CESP - Equipe 'Moods'- Univ Paris-Saclay, 94275 Le Kremlin Bicêtre, France
- Service de Psychiatrie- Hôpital Bicêtre- GH Paris Saclay- APHP, 94275 Le Kremlin Bicêtre, France
- Faculté de Médecine Paris-Saclay, 94275 Le Kremlin Bicêtre, France
| | - C Verstuyft
- INSERM CESP - Equipe 'Moods'- Univ Paris-Saclay, 94275 Le Kremlin Bicêtre, France
- Faculté de Médecine Paris-Saclay, 94275 Le Kremlin Bicêtre, France
- Service de Génétique moléculaire, Pharmacogénétique et Hormonologie- CHU de Bicêtre- APHP, 94275 Le Kremlin Bicêtre, France
| | - B Fève
- Sorbonne Université-INSERM UMR S_938, Centre de Recherche Saint-Antoine, 75012Paris, France
- Service d'Endocrinologie- Hôpital Saint-Antoine- APHP, 75012Paris, France
- Institut Hospitalo-Universitaire ICAN, 75012Paris, France
| | - P Chanson
- Faculté de Médecine Paris-Saclay, 94275 Le Kremlin Bicêtre, France
- Inserm U1185 - Univ Paris-Sud, 94275 Le Kremlin Bicêtre, France
- Service d'Endocrinologie et des Maladies de la Reproduction- CHU de Bicêtre- APHP, 94275 Le Kremlin Bicêtre, France
| | - L Becquemont
- INSERM CESP - Equipe 'Moods'- Univ Paris-Saclay, 94275 Le Kremlin Bicêtre, France
- Faculté de Médecine Paris-Saclay, 94275 Le Kremlin Bicêtre, France
- Service de Génétique moléculaire, Pharmacogénétique et Hormonologie- CHU de Bicêtre- APHP, 94275 Le Kremlin Bicêtre, France
| | - E Corruble
- INSERM CESP - Equipe 'Moods'- Univ Paris-Saclay, 94275 Le Kremlin Bicêtre, France
- Service de Psychiatrie- Hôpital Bicêtre- GH Paris Saclay- APHP, 94275 Le Kremlin Bicêtre, France
- Faculté de Médecine Paris-Saclay, 94275 Le Kremlin Bicêtre, France
| |
Collapse
|
6
|
Wolf P, Marty B, Bouazizi K, Kachenoura N, Piedvache C, Blanchard A, Salenave S, Prigent M, Jublanc C, Ajzenberg C, Droumaguet C, Young J, Lecoq AL, Kuhn E, Agostini H, Trabado S, Carlier PG, Fève B, Redheuil A, Chanson P, Kamenický P. Response to Letter to the Editor from Soghomonian: "Epicardial and Pericardial Adiposity Without Myocardial Steatosis in Cushing Syndrome". J Clin Endocrinol Metab 2022; 107:e443-e444. [PMID: 34519341 PMCID: PMC8684451 DOI: 10.1210/clinem/dgab678] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/31/2021] [Indexed: 11/19/2022]
Affiliation(s)
- Peter Wolf
- Université Paris-Saclay, Inserm, Physiologie et Physiopathologie Endocriniennes, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Service d’Endocrinologie et des Maladies de la Reproduction, Centre de Référence des Maladies Rares de l’Hypophyse, 94275 Le Kremlin-Bicêtre, France
- Medical University of Vienna, Department of Internal Medicine III, Division of Endocrinology and Metabolism, 1090 Vienna, Austria
| | - Benjamin Marty
- Institut de Myologie, CEA, Laboratoire de Résonance Magnétique Nucléaire, 75013 Paris, France
| | - Khaoula Bouazizi
- Institut de Cardiométabolisme et Nutrition (ICAN), 75013 Paris, France
- Sorbonne Université, CNRS, Inserm, Laboratoire d’Imagerie Biomédicale, LIB, 75006 Paris, France
| | - Nadjia Kachenoura
- Institut de Cardiométabolisme et Nutrition (ICAN), 75013 Paris, France
- Sorbonne Université, CNRS, Inserm, Laboratoire d’Imagerie Biomédicale, LIB, 75006 Paris, France
| | - Céline Piedvache
- Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Unité de Recherche Clinique, 94275 Le Kremlin-Bicêtre, France
| | - Anne Blanchard
- Université de Paris, Assistance Publique des Hôpitaux de Paris, Hôpital Européen Georges-Pompidou, Centre d’Investigations Cliniques, Inserm CIC1318 et UMR 1138, 75015 Paris, France
| | - Sylvie Salenave
- Université Paris-Saclay, Inserm, Physiologie et Physiopathologie Endocriniennes, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Service d’Endocrinologie et des Maladies de la Reproduction, Centre de Référence des Maladies Rares de l’Hypophyse, 94275 Le Kremlin-Bicêtre, France
| | - Mikaël Prigent
- Institut de Cardiométabolisme et Nutrition (ICAN), 75013 Paris, France
| | - Christel Jublanc
- Assistance Publique-Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service d’Endocrinologie-Métabolisme, 75013 Paris, France
| | - Christiane Ajzenberg
- Assistance Publique-Hôpitaux de Paris, Hôpital Henri-Mondor, Service de Médecine Interne, 94000 Créteil, France
| | - Céline Droumaguet
- Assistance Publique-Hôpitaux de Paris, Hôpital Henri-Mondor, Service de Médecine Interne, 94000 Créteil, France
| | - Jacques Young
- Université Paris-Saclay, Inserm, Physiologie et Physiopathologie Endocriniennes, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Service d’Endocrinologie et des Maladies de la Reproduction, Centre de Référence des Maladies Rares de l’Hypophyse, 94275 Le Kremlin-Bicêtre, France
| | - Anne-Lise Lecoq
- Université Paris-Saclay, Inserm, Physiologie et Physiopathologie Endocriniennes, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Service d’Endocrinologie et des Maladies de la Reproduction, Centre de Référence des Maladies Rares de l’Hypophyse, 94275 Le Kremlin-Bicêtre, France
| | - Emmanuelle Kuhn
- Université Paris-Saclay, Inserm, Physiologie et Physiopathologie Endocriniennes, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Service d’Endocrinologie et des Maladies de la Reproduction, Centre de Référence des Maladies Rares de l’Hypophyse, 94275 Le Kremlin-Bicêtre, France
| | - Helene Agostini
- Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Unité de Recherche Clinique, 94275 Le Kremlin-Bicêtre, France
| | - Severine Trabado
- Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Service de Génétique Moléculaire, Pharmacogénétique et Hormonologie, 94275 Le Kremlin-Bicêtre, France
| | - Pierre G Carlier
- Institut de Myologie, CEA, Laboratoire de Résonance Magnétique Nucléaire, 75013 Paris, France
| | - Bruno Fève
- Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Antoine, Service d’Endocrinologie et Métabolisme, Centre de Référence des Maladies Rares de l’Insulino-Sécrétion et de l’Insulino-Sensibilité (PRISIS), Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, UMR-S938, IHU ICAN, 75012 Paris, France
| | - Alban Redheuil
- Sorbonne Université, CNRS, Inserm, Laboratoire d’Imagerie Biomédicale, LIB, 75006 Paris, France
- Assistance Publique-Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Unité d’Imagerie Cardiovasculaire et Thoracique, APHP.SU, 75013 Paris, France
| | - Philippe Chanson
- Université Paris-Saclay, Inserm, Physiologie et Physiopathologie Endocriniennes, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Service d’Endocrinologie et des Maladies de la Reproduction, Centre de Référence des Maladies Rares de l’Hypophyse, 94275 Le Kremlin-Bicêtre, France
| | - Peter Kamenický
- Université Paris-Saclay, Inserm, Physiologie et Physiopathologie Endocriniennes, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Service d’Endocrinologie et des Maladies de la Reproduction, Centre de Référence des Maladies Rares de l’Hypophyse, 94275 Le Kremlin-Bicêtre, France
- Correspondence: Peter Kamenický, MD, PhD, Faculté de Médecine Paris-Saclay, 63 rue Gabriel Péri, 94276 Le Kremlin Bicêtre Cedex, France.
| |
Collapse
|
7
|
Wolf P, Marty B, Bouazizi K, Kachenoura N, Piedvache C, Blanchard A, Salenave S, Prigent M, Jublanc C, Ajzenberg C, Droumaguet C, Young J, Lecoq AL, Kuhn E, Agostini H, Trabado S, Carlier PG, Fève B, Redheuil A, Chanson P, Kamenický P. Epicardial and Pericardial Adiposity Without Myocardial Steatosis in Cushing Syndrome. J Clin Endocrinol Metab 2021; 106:3505-3514. [PMID: 34333603 DOI: 10.1210/clinem/dgab556] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/28/2021] [Indexed: 11/19/2022]
Abstract
CONTEXT Cardiovascular disease is the leading cause of death in patients with Cushing syndrome. Cortisol excess and adverse metabolic profile could increase cardiac fat, which can subsequently impair cardiac structure and function. OBJECTIVE We aimed to evaluate cardiac fat mass and distribution in patients with Cushing syndrome. METHODS In this prospective, cross-sectional study, 23 patients with Cushing syndrome and 27 control individuals of comparable age, sex, and body mass index were investigated by cardiac magnetic resonance imaging and proton spectroscopy. Patients were explored before and after biochemical disease remission. Myocardial fat measured by the Dixon method was the main outcome measure. The intramyocardial triglyceride/water ratio measured by spectroscopy and epicardial and pericardial fat volumes were secondary outcome measures. RESULTS No difference was found between patients and controls in intramyocardial lipid content. Epicardial fat mass was increased in patients compared to controls (30.8 g/m2 [20.4-34.8] vs 17.2 g/m2 [13.1-23.5], P < .001). Similarly, pericardial fat mass was increased in patients compared to controls (28.3 g/m2 [17.9-38.0] vs 11.4 g/m2 [7.5-19.4], P = .003). Sex, glycated hemoglobin A1c, and the presence of hypercortisolism were independent determinants of epicardial fat. Pericardial fat was associated with sex, impaired glucose homeostasis and left ventricular wall thickness. Disease remission decreased epicardial fat mass without affecting pericardial fat. CONCLUSION Intramyocardial fat stores are not increased in patients with Cushing syndrome, despite highly prevalent metabolic syndrome, suggesting increased cortisol-mediated lipid consumption. Cushing syndrome is associated with marked accumulation of epicardial and pericardial fat. Epicardial adiposity may exert paracrine proinflammatory effects promoting cardiomyopathy.
Collapse
Affiliation(s)
- Peter Wolf
- Université Paris-Saclay, Inserm, Physiologie et Physiopathologie Endocriniennes, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Service d'Endocrinologie et des Maladies de la Reproduction, Centre de Référence des Maladies Rares de l'Hypophyse, 94275 Le Kremlin-Bicêtre, France
- Medical University of Vienna, Department of Internal Medicine III, Division of Endocrinology and Metabolism, 1090 Vienna, Austria
| | - Benjamin Marty
- Institut de Myologie, CEA, Laboratoire de Résonance Magnétique Nucléaire, 75013 Paris, France
| | - Khaoula Bouazizi
- Institut de Cardiométabolisme et Nutrition (ICAN), 75013 Paris, France
- Sorbonne Université, CNRS, Inserm, Laboratoire d'Imagerie Biomédicale, LIB, 75006 Paris, France
| | - Nadjia Kachenoura
- Institut de Cardiométabolisme et Nutrition (ICAN), 75013 Paris, France
- Sorbonne Université, CNRS, Inserm, Laboratoire d'Imagerie Biomédicale, LIB, 75006 Paris, France
| | - Céline Piedvache
- Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Unité de Recherche Clinique, 94275 Le Kremlin-Bicêtre, France
| | - Anne Blanchard
- Université de Paris, Assistance Publique des Hôpitaux de Paris, Hôpital Européen Georges-Pompidou, Centre d'Investigations Cliniques, Inserm CIC1318 et UMR 1138, 75015 Paris, France
| | - Sylvie Salenave
- Université Paris-Saclay, Inserm, Physiologie et Physiopathologie Endocriniennes, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Service d'Endocrinologie et des Maladies de la Reproduction, Centre de Référence des Maladies Rares de l'Hypophyse, 94275 Le Kremlin-Bicêtre, France
| | - Mikaël Prigent
- Institut de Cardiométabolisme et Nutrition (ICAN), 75013 Paris, France
| | - Christel Jublanc
- Assistance Publique-Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service d'Endocrinologie-Métabolisme, 75013 Paris, France
| | - Christiane Ajzenberg
- Assistance Publique-Hôpitaux de Paris, Hôpital Henri-Mondor, Service de Médecine Interne, 94000 Créteil, France
| | - Céline Droumaguet
- Assistance Publique-Hôpitaux de Paris, Hôpital Henri-Mondor, Service de Médecine Interne, 94000 Créteil, France
| | - Jacques Young
- Université Paris-Saclay, Inserm, Physiologie et Physiopathologie Endocriniennes, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Service d'Endocrinologie et des Maladies de la Reproduction, Centre de Référence des Maladies Rares de l'Hypophyse, 94275 Le Kremlin-Bicêtre, France
| | - Anne-Lise Lecoq
- Université Paris-Saclay, Inserm, Physiologie et Physiopathologie Endocriniennes, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Service d'Endocrinologie et des Maladies de la Reproduction, Centre de Référence des Maladies Rares de l'Hypophyse, 94275 Le Kremlin-Bicêtre, France
| | - Emmanuelle Kuhn
- Université Paris-Saclay, Inserm, Physiologie et Physiopathologie Endocriniennes, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Service d'Endocrinologie et des Maladies de la Reproduction, Centre de Référence des Maladies Rares de l'Hypophyse, 94275 Le Kremlin-Bicêtre, France
| | - Helene Agostini
- Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Unité de Recherche Clinique, 94275 Le Kremlin-Bicêtre, France
| | - Severine Trabado
- Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Service de Génétique Moléculaire, Pharmacogénétique et Hormonologie, 94275 Le Kremlin-Bicêtre, France
| | - Pierre G Carlier
- Institut de Myologie, CEA, Laboratoire de Résonance Magnétique Nucléaire, 75013 Paris, France
| | - Bruno Fève
- Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Antoine, Service d'Endocrinologie et Métabolisme, Centre de Référence des Maladies Rares de l'Insulino-Sécrétion et de l'Insulino-Sensibilité (PRISIS), Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, UMR-S938, IHU ICAN, 75012 Paris, France
| | - Alban Redheuil
- Sorbonne Université, CNRS, Inserm, Laboratoire d'Imagerie Biomédicale, LIB, 75006 Paris, France
- Assistance Publique-Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Unité d'Imagerie Cardiovasculaire et Thoracique, APHP.SU, 75013 Paris, France
| | - Philippe Chanson
- Université Paris-Saclay, Inserm, Physiologie et Physiopathologie Endocriniennes, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Service d'Endocrinologie et des Maladies de la Reproduction, Centre de Référence des Maladies Rares de l'Hypophyse, 94275 Le Kremlin-Bicêtre, France
| | - Peter Kamenický
- Université Paris-Saclay, Inserm, Physiologie et Physiopathologie Endocriniennes, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Service d'Endocrinologie et des Maladies de la Reproduction, Centre de Référence des Maladies Rares de l'Hypophyse, 94275 Le Kremlin-Bicêtre, France
| |
Collapse
|
8
|
Ostertag A, Papadakis GE, Collet C, Trabado S, Maione L, Pitteloud N, Bouligand J, De Vernejoul MC, Cohen-Solal M, Young J. Compromised Volumetric Bone Density and Microarchitecture in Men With Congenital Hypogonadotropic Hypogonadism. J Clin Endocrinol Metab 2021; 106:e3312-e3326. [PMID: 33725720 DOI: 10.1210/clinem/dgab169] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/31/2020] [Indexed: 11/19/2022]
Abstract
CONTEXT Men with congenital hypogonadotropic hypogonadism (CHH) and Kallmann syndrome (KS) have both low circulating testosterone and estradiol levels. Whether bone structure is affected remains unknown. OBJECTIVE To characterize bone geometry, volumetric density and microarchitecture in CHH/KS. METHODS This cross-sectional study, conducted at a single French tertiary academic medical center, included 51 genotyped CHH/KS patients and 40 healthy volunteers. Among CHH/KS men, 98% had received testosterone and/or combined gonadotropins. High-resolution peripheral quantitative computed tomography (HR-pQCT), dual-energy x-ray absorptiometry (DXA), and measurement of serum bone markers were used to determine volumetric bone mineral density (vBMD) and cortical and trabecular microarchitecture. RESULTS CHH and controls did not differ for age, body mass index, and levels of vitamin D and PTH. Despite long-term hormonal treatment (10.8 ± 6.8 years), DXA showed lower areal bone mineral density (aBMD) in CHH/KS at lumbar spine, total hip, femoral neck, and distal radius. Consistent with persistently higher serum bone markers, HR-pQCT revealed lower cortical and trabecular vBMD as well as cortical thickness at the tibia and the radius. CHH/KS men had altered trabecular microarchitecture with a predominant decrease of trabecular thickness. Moreover, CHH/KS men exhibited lower cortical bone area, whereas total and trabecular areas were higher only at the tibia. Earlier treatment onset (before age 19 years) conferred a significant advantage for trabecular bone volume/tissue volume and trabecular vBMD at the tibia. CONCLUSION Both vBMD and bone microarchitecture remain impaired in CHH/KS men despite long-term hormonal treatment. Treatment initiation during adolescence is associated with enhanced trabecular outcomes, highlighting the importance of early diagnosis.
Collapse
Affiliation(s)
- Agnès Ostertag
- Department of Rheumatology, Université de Paris and INSERM UMR-U1132 (Biology of bone and cartilage research unit), Hôpital Lariboisière, F-75010 Paris, France
| | - Georgios E Papadakis
- Service of Endocrinology, Diabetes and Metabolism, Lausanne University Hospital, CH-1011, Lausanne, Switzerland
- Department of Reproductive Endocrinology, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, F-94275, Le Kremlin-Bicêtre, France
| | - Corinne Collet
- Service de Biochimie et de Génétique Moléculaire, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, France and INSERM UMR-U1132, UFR Sciences pharmaceutiques et biologiques - Faculté de pharmacie, Université de Paris, France
| | - Severine Trabado
- Service de Génétique Moléculaire, Pharmacogénétique et Hormonologie, Hôpitaux Universitaires Paris Saclay, Assistance Publique-Hôpitaux de Paris, CHU Bicêtre, F-94275,France
- INSERM UMR-U1185, Fac Med Paris Saclay, Université Paris Saclay, Le Kremlin-Bicêtre, F-94276, France
- University Paris Saclay, F-91405 Orsay cedex, France
| | - Luigi Maione
- Department of Reproductive Endocrinology, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, F-94275, Le Kremlin-Bicêtre, France
- INSERM UMR-U1185, Fac Med Paris Saclay, Université Paris Saclay, Le Kremlin-Bicêtre, F-94276, France
- University Paris Saclay, F-91405 Orsay cedex, France
| | - Nelly Pitteloud
- Service of Endocrinology, Diabetes and Metabolism, Lausanne University Hospital, CH-1011, Lausanne, Switzerland
- Faculty of Biology and Medicine, University of Lausanne, CH-1011, Lausanne, Switzerland
| | - Jerome Bouligand
- Service de Génétique Moléculaire, Pharmacogénétique et Hormonologie, Hôpitaux Universitaires Paris Saclay, Assistance Publique-Hôpitaux de Paris, CHU Bicêtre, F-94275,France
- INSERM UMR-U1185, Fac Med Paris Saclay, Université Paris Saclay, Le Kremlin-Bicêtre, F-94276, France
- University Paris Saclay, F-91405 Orsay cedex, France
| | - Marie Christine De Vernejoul
- Department of Rheumatology, Université de Paris and INSERM UMR-U1132 (Biology of bone and cartilage research unit), Hôpital Lariboisière, F-75010 Paris, France
| | - Martine Cohen-Solal
- Department of Rheumatology, Université de Paris and INSERM UMR-U1132 (Biology of bone and cartilage research unit), Hôpital Lariboisière, F-75010 Paris, France
| | - Jacques Young
- Department of Reproductive Endocrinology, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, F-94275, Le Kremlin-Bicêtre, France
- INSERM UMR-U1185, Fac Med Paris Saclay, Université Paris Saclay, Le Kremlin-Bicêtre, F-94276, France
- University Paris Saclay, F-91405 Orsay cedex, France
| |
Collapse
|
9
|
Ait Tayeb AEK, Becquemont L, El-Asmar K, Mahmoudi K, Colle R, Trabado S, Gressier F, Feve B, Corruble E, Verstuyft C. SOD2 genetic polymorphism (rs4880) has no impact on 6-month response to antidepressant treatment and inflammatory biomarkers in depressed patients. Basic Clin Pharmacol Toxicol 2020; 126:289-295. [PMID: 31904901 DOI: 10.1111/bcpt.13385] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2019] [Accepted: 12/27/2019] [Indexed: 12/17/2022]
Abstract
Two thirds of patients suffering from a major depressive episode (MDE) do not reach a complete response with antidepressant drugs. This lack of response is due to several factors, including genetic determinants. Since major depressive disorder is associated with inflammatory and oxidative stress abnormalities, the metabolism of superoxide anions might be involved in non-response to antidepressant drugs. Superoxide anions are metabolized by manganese-dependent superoxide dismutase (SOD2) in the mitochondria. A functional genetic polymorphism (SOD2, rs4880), responsible of a 40% reduction in enzyme activity, is associated with anti-inflammatory response of rosuvastatin. We investigated the association of ala-allele of SOD2 rs4880 and both antidepressant efficacy and inflammatory parameters in patients treated for a MDE with antidepressant drugs. The Hamilton Depression Rating Scale (HDRS) score and levels of plasma CRP and inflammatory cytokines were assessed at baseline, one month (M1), 3 months (M3) and 6 months (M6) after antidepressant treatment. They were compared according to SOD2 genetic polymorphism. Of the 484 patients studied, 361 (74.6%) carried the ala-allele (Ala group), 123 (25.4%) of them had Val/Val genotype (Val/Val group). No significant difference was observed between the Ala and Val/Val groups neither for baseline clinical characteristics, nor for HDRS scores, response/remission rates, plasma CRP and cytokine levels throughout the study. The rs4880 SOD2 genetic polymorphism was not associated with the clinical response and cytokines levels after antidepressant treatment. These data suggest that SOD2 is not a major genetic determinant of antidepressant response. Other genes of the oxidative stress pathways should be explored in further studies.
Collapse
Affiliation(s)
- Abd El Kader Ait Tayeb
- CESP, Team "Moods", Faculty of Medicine Paris-Saclay, University Paris-Saclay, INSERM, Le Kremlin Bicêtre, France.,Psychiatry Department, Bicetre Hospital, Paris-Saclay University Hospitals, AP-HP, Le Kremlin Bicêtre, France.,Molecular Genetics, Pharmacogenetics and Hormonology Department, Paris-Saclay University Hospitals, AP-HP, Le Kremlin Bicêtre, France
| | - Laurent Becquemont
- CESP, Team "Moods", Faculty of Medicine Paris-Saclay, University Paris-Saclay, INSERM, Le Kremlin Bicêtre, France.,Molecular Genetics, Pharmacogenetics and Hormonology Department, Paris-Saclay University Hospitals, AP-HP, Le Kremlin Bicêtre, France
| | - Khalil El-Asmar
- CESP, Team "Moods", Faculty of Medicine Paris-Saclay, University Paris-Saclay, INSERM, Le Kremlin Bicêtre, France
| | - Kaïna Mahmoudi
- CESP, Team "Moods", Faculty of Medicine Paris-Saclay, University Paris-Saclay, INSERM, Le Kremlin Bicêtre, France
| | - Romain Colle
- CESP, Team "Moods", Faculty of Medicine Paris-Saclay, University Paris-Saclay, INSERM, Le Kremlin Bicêtre, France.,Psychiatry Department, Bicetre Hospital, Paris-Saclay University Hospitals, AP-HP, Le Kremlin Bicêtre, France
| | - Severine Trabado
- Molecular Genetics, Pharmacogenetics and Hormonology Department, Paris-Saclay University Hospitals, AP-HP, Le Kremlin Bicêtre, France.,INSERM UMR-S U1185, Faculty of Medicine Paris-Saclay, University Paris-Saclay, Le Kremlin Bicêtre, France
| | - Florence Gressier
- CESP, Team "Moods", Faculty of Medicine Paris-Saclay, University Paris-Saclay, INSERM, Le Kremlin Bicêtre, France.,Psychiatry Department, Bicetre Hospital, Paris-Saclay University Hospitals, AP-HP, Le Kremlin Bicêtre, France
| | - Bruno Feve
- Endocrinology Department, Sorbonne University-INSERM, Research Center of Saint-Antoine, ICAN University Hospital Institute, Saint-Antoine Hospital, AP-HP, Paris, France
| | - Emmanuelle Corruble
- CESP, Team "Moods", Faculty of Medicine Paris-Saclay, University Paris-Saclay, INSERM, Le Kremlin Bicêtre, France.,Psychiatry Department, Bicetre Hospital, Paris-Saclay University Hospitals, AP-HP, Le Kremlin Bicêtre, France
| | - Céline Verstuyft
- CESP, Team "Moods", Faculty of Medicine Paris-Saclay, University Paris-Saclay, INSERM, Le Kremlin Bicêtre, France.,Molecular Genetics, Pharmacogenetics and Hormonology Department, Paris-Saclay University Hospitals, AP-HP, Le Kremlin Bicêtre, France
| |
Collapse
|
10
|
Fraichard C, Bonnet F, Garnier A, Hébert-Schuster M, Bouzerara A, Gerbaud P, Ferecatu I, Fournier T, Hernandez I, Trabado S, Guibourdenche J. Placental production of progestins is fully effective in villous cytotrophoblasts and increases with the syncytiotrophoblast formation. Mol Cell Endocrinol 2020; 499:110586. [PMID: 31539598 DOI: 10.1016/j.mce.2019.110586] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/13/2019] [Revised: 09/06/2019] [Accepted: 09/16/2019] [Indexed: 01/18/2023]
Abstract
Placental syncytiotrophoblast (ST) is considered as the main placental endocrine tissue secreting progesterone, a steroid essential for maintenance of pregnancy. However, each step of progestins production has been poorly investigated in villous cytotrophoblast (VCT) regarding ST formation. We aimed to characterize progestins production during human differentiation of VCT into ST. VCTs were isolated from term placenta and cultivated, with or without forskolin (FSK), to stimulate trophoblast differentiation. Secreted progestins concentrations were determined by immuno-assay and Gas Chromatography-tandem mass spectrometry. Intracellular expression of cholesterol transporter and enzymes involved in steroidogenesis were studied by immunofluorescence, western-blot, and RT-qPCR. Progesterone and pregnenolone are produced by VCT and their secretion increases with VCT differentiation while 17-hydroxyprogesterone concentration remains undetectable. HSD3B1 enzyme expression increases whereas MLN64, the cholesterol placental mitochondrial transporter and P450SCC expressions do not. FSK induces progestins production. Progestins placental synthesis is effective since VCT and increases with ST formation thanks to mitochondria.
Collapse
Affiliation(s)
- C Fraichard
- UMR-S 1139, Faculté de Pharmacie, Université Paris Descartes, Paris, France
| | - F Bonnet
- Service d' Hormonologie, CHU Cochin, HUPC, AP-HP, Paris, France
| | - A Garnier
- Service de Génétique Moléculaire, Pharmacogénétique et Hormonologie, Hôpitaux Universitaires Paris-Sud, CHU de Bicêtre, AP-HP, Le Kremlin Bicêtre, France; UMR-S U1185, Faculté de Médecine Paris-Sud, Université Paris-Sud, Université Paris-Saclay, Le Kremlin Bicêtre, France
| | - M Hébert-Schuster
- UMR-S 1139, Faculté de Pharmacie, Université Paris Descartes, Paris, France; Service d' Hormonologie, CHU Cochin, HUPC, AP-HP, Paris, France
| | - A Bouzerara
- UMR-S 1139, Faculté de Pharmacie, Université Paris Descartes, Paris, France; Service d' Hormonologie, CHU Cochin, HUPC, AP-HP, Paris, France
| | - P Gerbaud
- UMR-S 1180, Faculté de Pharmacie, 5 Rue JB Clément, 92296, Châtenay-Malabry, France
| | - I Ferecatu
- UMR-S 1139, Faculté de Pharmacie, Université Paris Descartes, Paris, France
| | - T Fournier
- UMR-S 1139, Faculté de Pharmacie, Université Paris Descartes, Paris, France
| | - I Hernandez
- UMR-S 1139, Faculté de Pharmacie, Université Paris Descartes, Paris, France
| | - S Trabado
- Service de Génétique Moléculaire, Pharmacogénétique et Hormonologie, Hôpitaux Universitaires Paris-Sud, CHU de Bicêtre, AP-HP, Le Kremlin Bicêtre, France; UMR-S U1185, Faculté de Médecine Paris-Sud, Université Paris-Sud, Université Paris-Saclay, Le Kremlin Bicêtre, France
| | - J Guibourdenche
- UMR-S 1139, Faculté de Pharmacie, Université Paris Descartes, Paris, France; Service d' Hormonologie, CHU Cochin, HUPC, AP-HP, Paris, France.
| |
Collapse
|
11
|
Mosbah H, Bouvattier C, Maione L, Trabado S, Gianpaolo DP, Alejandra C, Aurelie D, Chanson P, Brailly Tabard S, Coutant R, Young J. MON-244 GnRH Test Does Not Efficiently Discriminate Congenital Isolated Hypogonadotropic Hypogonadism from Constitutional Delay of Growth and Puberty in Males. J Endocr Soc 2019. [PMCID: PMC6551093 DOI: 10.1210/js.2019-mon-244] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
Context: Delayed puberty can be due to either constitutional delay of growth and puberty (CDGP) or congenital hypogonadotropic hypogonadism (CHH). Differentiating between the two conditions either clinically or using current hormonal testing is difficult. GnRH test is currently used in many centers to differentiate CDGP from CHH but its diagnostic performance was not assessed in a significant number of CHH patients. Objective: To compare gonadotropin responses to GnRH challenge between CHH and C and to assess the diagnostic performance of this test in large cohorts of CHH and CDGP. Subjects: We included 127 men with CHH (68 Kallmann Syndrome (KS) and 69 normosmic CHH; age: 25.5±9.9 y), 74 men with CDGP (14.9±1.0 y) not treated, 31 control (C) men (25.9±5.2 y). Methods: Testicular volume (TV) was measured. Basal testosterone and inhibin B (IB, limit of detection: 3 pg/mL) were measured using sensitive immunoassays. Intravenous injection of 100 μg GnRH was performed. Serum FSH and LH were measured (at -15, 0, 15, 30, 60, and 120 min) using sensitive immunoradiometric assays with a detection limit of 0.05 IU/L for both gonadotropins. Results (mean±SD, [range]): Testosterone levels (ng/mL) were: C, 6.5±1.2 [4.2-8.7]; CHH/KS, 0.5±0.4 [0.0-2.1]; CDGP, 0.6±0.6 [0.0-2.5]. Testicular volumes (mL) were respectively in CHH/KS and CDGP: 3.1±2.8 [0.1-13.5] and 4.5±2.7 [0.7-10]. LH basal and peaks (IU/L) were: C, basal: 4.2±0.9 [2.9-6.1], peak 17.9±3.7 [11.1-26.0]; CHH/KS, basal 0.8±1.0 [0.1-4.2], peak: 6.9±7.8 [0.1-41.5]; CDGP, basal: 1.3±0.8 [0.1-3.7]; peak: 13.9±6.3 [4.0-33.4]. In 25/127 (21%) of CHH/KS, we found an overlapping in serum LH peaks levels when compared to C. Importantly, in 47% (60/127) of CHH/KS patients, GnRH-induced LH peaks overlapped with LH peak values observed in CDGP. However, none of the patients with CDGP had LH peak values below 4.0 IU/L while 68/127 (53%) of those with CHH/KS had LH peak levels below this threshold. In CHH/KS and CDGP, serum IB were respectively (58±64 [3-311] and 164±97 [35-630]). In 59% of untreated CHH/KS patients, serum IB overlapped with CDGP. In CHH, we found a significant positive correlation between LH peak and TV (r=0.41; p < 0.0001) and a stronger positive correlation between LH peak and IB (r=0.49; p< 0.0001). Conclusion: In both CHH/KS and CDGP, the ranges of GnRH induced LH peaks were very wide and a strong overlapping was found between the three groups studied. Both LH peak and IB were correlated with the severity of gonadotropin deficiency as reflected by TV. The GnRH challenge test is not efficient enough to discriminate CHH/KS from CDGP but very weak LH responses (4 IU/L) were specifically observed in CHH/KS. Diagnosis efficiency of serum IB will also be discussed.
Collapse
Affiliation(s)
- Helena Mosbah
- Bicetre Hospital, Paris Sud University, Department of Reproductive Endocrinology, LE KREMLIN-BICETRE, , France
| | - Claire Bouvattier
- Bicetre Hospital, Paris Sud University, Department of Pediatric Endocrinology, LE KREMLIN-BICETRE, , France
| | - Luigi Maione
- Bicetre Hospital, Paris Sud University, Department of Reproductive Endocrinology, LE KREMLIN-BICETRE, , France
| | - Severine Trabado
- Bicetre Hospital, Paris Sud University, Department of Hormonology and Molecular Genetics, LE KREMLIN-BICETRE, , France
| | - De Philippo Gianpaolo
- Bicetre Hospital, Paris Sud University, Department of Reproductive Endocrinology, LE KREMLIN-BICETRE, , France
| | - Cartes Alejandra
- Bicetre Hospital, Paris Sud University, Department of Reproductive Endocrinology, LE KREMLIN-BICETRE, , France
| | - Donzeau Aurelie
- CHRU HOTEL-DIEU, Department of Pediatric Endocrinology, Angers, , France
| | - Philippe Chanson
- Endocrinology, Bicetre Hospital, Paris Sud University, Department of Reproductive Endocrinology, LE KREMLIN-BICETRE, , France
| | - Sylvie Brailly Tabard
- Bicetre Hospital, Paris Sud University, Department of Hormonology and Molecular Genetics, LE KREMLIN-BICETRE, , France
| | - Regis Coutant
- DEPT OF PEDIATRIC, CHRU HOTEL-DIEU, Department of Pediatric Endocrinology, Angers, , France
| | - Jacques Young
- Dept. of Endo and Reproduction, Bicetre Hospital, Paris Sud University, Department of Reproductive Endocrinology, LE KREMLIN-BICETRE, , France
| |
Collapse
|
12
|
Corruble E, El Asmar K, Trabado S, Verstuyft C, Falissard B, Colle R, Petit AC, Gressier F, Brailly-Tabard S, Ferreri F, Lépine JP, Haffen E, Polosan M, Bourrier C, Perlemuter G, Chanson P, Fève B, Becquemont L. Treating major depressive episodes with antidepressants can induce or worsen metabolic syndrome: results of the METADAP cohort. World Psychiatry 2015; 14:366-7. [PMID: 26407797 PMCID: PMC4592664 DOI: 10.1002/wps.20260] [Citation(s) in RCA: 41] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Affiliation(s)
- Emmanuelle Corruble
- University Paris-SudLe Kremlin Bicêtre, France,Institut National de la Santé et de la Recherche Médicale UMR-1178Le Kremlin Bicêtre, France,Hôpitaux Universitaires Paris-SudLe Kremlin Bicêtre, France,Hôpital de BicêtreLe Kremlin Bicêtre, France
| | - Khalil El Asmar
- Institut National de la Santé et de la Recherche Médicale UMR-1178Le Kremlin Bicêtre, France
| | - Severine Trabado
- University Paris-SudLe Kremlin Bicêtre, France,Hôpitaux Universitaires Paris-SudLe Kremlin Bicêtre, France,Hôpital de BicêtreLe Kremlin Bicêtre, France,Institut National de la Santé et de la Recherche Médicale UMR-S1185Le Kremlin Bicêtre, France
| | - Céline Verstuyft
- University Paris-SudLe Kremlin Bicêtre, France,Hôpitaux Universitaires Paris-SudLe Kremlin Bicêtre, France,Hôpital de BicêtreLe Kremlin Bicêtre, France,Institut National de la Santé et de la Recherche Médicale U1184Le Kremlin Bicêtre, France
| | - Bruno Falissard
- University Paris-SudLe Kremlin Bicêtre, France,Institut National de la Santé et de la Recherche Médicale UMR-1178Le Kremlin Bicêtre, France,Hôpitaux Universitaires Paris-SudLe Kremlin Bicêtre, France,Hôpital Paul BrousseVillejuif, France
| | - Romain Colle
- University Paris-SudLe Kremlin Bicêtre, France,Institut National de la Santé et de la Recherche Médicale UMR-1178Le Kremlin Bicêtre, France,Hôpitaux Universitaires Paris-SudLe Kremlin Bicêtre, France,Hôpital de BicêtreLe Kremlin Bicêtre, France
| | - Anne-Cécile Petit
- Institut National de la Santé et de la Recherche Médicale UMR-1178Le Kremlin Bicêtre, France
| | - Florence Gressier
- University Paris-SudLe Kremlin Bicêtre, France,Institut National de la Santé et de la Recherche Médicale UMR-1178Le Kremlin Bicêtre, France,Hôpitaux Universitaires Paris-SudLe Kremlin Bicêtre, France,Hôpital de BicêtreLe Kremlin Bicêtre, France
| | - Sylvie Brailly-Tabard
- University Paris-SudLe Kremlin Bicêtre, France,Hôpitaux Universitaires Paris-SudLe Kremlin Bicêtre, France,Hôpital de BicêtreLe Kremlin Bicêtre, France,Institut National de la Santé et de la Recherche Médicale UMR-S1185Le Kremlin Bicêtre, France
| | - Florian Ferreri
- Université Pierre et Marie CurieParis, France,Service de Psychiatrie, Hôpital Saint-AntoineParis, France
| | | | | | | | - Céline Bourrier
- Institut National de la Santé et de la Recherche Médicale UMR-1178Le Kremlin Bicêtre, France
| | - Gabriel Perlemuter
- University Paris-SudLe Kremlin Bicêtre, France,Hôpitaux Universitaires Paris-SudLe Kremlin Bicêtre, France,Institut National de la Santé et de la Recherche Médicale UMR-996Clamart, France,Hôpital Antoine-BéclèreClamart, France
| | - Philippe Chanson
- University Paris-SudLe Kremlin Bicêtre, France,Hôpitaux Universitaires Paris-SudLe Kremlin Bicêtre, France,Hôpital de BicêtreLe Kremlin Bicêtre, France,Institut National de la Santé et de la Recherche Médicale UMR-S1185Le Kremlin Bicêtre, France,Institut National de la Santé et de la Recherche Médicale U1185Le Kremlin Bicêtre, France
| | - Bruno Fève
- Service de Psychiatrie, Hôpital Saint-AntoineParis, France,Institut Hospitalo-Universitaire ICANParis, France,Service d’Endocrinologie, Hôpital Saint-AntoineParis, France
| | - Laurent Becquemont
- University Paris-SudLe Kremlin Bicêtre, France,Hôpitaux Universitaires Paris-SudLe Kremlin Bicêtre, France,Hôpital de BicêtreLe Kremlin Bicêtre, France,Institut National de la Santé et de la Recherche Médicale U1184Le Kremlin Bicêtre, France
| |
Collapse
|
13
|
Tordjman S, Anderson GM, Kermarrec S, Bonnot O, Geoffray MM, Brailly-Tabard S, Chaouch A, Colliot I, Trabado S, Bronsard G, Coulon N, Botbol M, Charbuy H, Camus F, Touitou Y. Altered circadian patterns of salivary cortisol in low-functioning children and adolescents with autism. Psychoneuroendocrinology 2014; 50:227-45. [PMID: 25244637 DOI: 10.1016/j.psyneuen.2014.08.010] [Citation(s) in RCA: 53] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/07/2014] [Revised: 08/14/2014] [Accepted: 08/18/2014] [Indexed: 12/28/2022]
Abstract
BACKGROUND Reports of higher stress responsivity, altered sleep-wake cycle and a melatonin deficit in autism have stimulated interest in the cortisol circadian rhythm in individuals with autism. METHODS The study was conducted on 55 low-functioning children and adolescents with autism (11.3 ± 4.1 years-old) and 32 typically developing controls (11.7 ± 4.9 years-old) matched for age, sex and puberty. Behavioral assessment was performed using the Autism Diagnostic Observation Schedule (ADOS). Salivary samples for measurement of cortisol were collected during a 24-h period (at least 0800 h-Day 1, 1600 h, 0800 h-Day 2 for 46 individuals with autism and 27 controls, and 0800 h-Day 1, 1100 h, 1600 h, 2400 h, 0800 h-Day 2 for 13 individuals with autism and 20 controls). Overnight (2000 h-0800 h) urinary cortisol excretion was also measured. RESULTS The autism group displayed significantly higher levels of salivary cortisol at all time-points, flatter daytime and nighttime slopes, higher 0800 h cortisol levels on Day 2 compared to Day 1, and greater variances of salivary and urinary cortisol. There was a significant relationship between salivary cortisol levels and impairments in social interaction and verbal language. Overnight urinary cortisol excretion was similar in the autism and control groups. CONCLUSION Anticipation of the stressful collection procedure appears to contribute to the higher 0800 h-Day 2 versus 0800 h-Day 1 salivary cortisol levels in autism. This sensitization to stressors might be as, or even more, important clinically than exposure to novelty in autism. The similar group means for overnight urinary cortisol excretion indicate that basal HPA axis functioning is unaltered in low-functioning autism. The elevated salivary cortisol levels observed in autism over the 24-h period in a repeated stressful condition, flattened diurnal cortisol patterns and the apparent effect of anticipation are consistent with prior findings in high trait anxiety.
Collapse
Affiliation(s)
- Sylvie Tordjman
- Pôle Hospitalo-Universitaire de Psychiatrie de l'Enfant et de l'Adolescent de Rennes (PHUPEA), CHGR et Université de Rennes 1, Rennes, France; Laboratoire Psychologie de la Perception, Université Paris Descartes, CNRS UMR 8158, Paris, France.
| | - George M Anderson
- Child Study Center, Yale University School of Medicine, New-Haven, CT, USA
| | - Solenn Kermarrec
- Pôle Hospitalo-Universitaire de Psychiatrie de l'Enfant et de l'Adolescent de Rennes (PHUPEA), CHGR et Université de Rennes 1, Rennes, France; Laboratoire Psychologie de la Perception, Université Paris Descartes, CNRS UMR 8158, Paris, France
| | - Olivier Bonnot
- Service Universitaire de Psychiatrie de l'Enfant et de l'Adolescent, CHU de Nantes, Nantes, France
| | - Marie-Maude Geoffray
- Service Universitaire de Psychiatrie de l'Enfant et de l'Adolescent, Hôpital le Vinatier, Bron, France
| | - Sylvie Brailly-Tabard
- INSERM U 693, Université Paris-Sud, Faculté de Médecine Paris-Sud, Le Kremlin-Bicêtre, France; AP-HP, CHU Bicêtre, Service de Génétique Moléculaire, Pharmacogénétique et Hormonologie, Le Kremlin-Bicêtre, France
| | - Amel Chaouch
- AP-HP, CHU Bicêtre, Service de Génétique Moléculaire, Pharmacogénétique et Hormonologie, Le Kremlin-Bicêtre, France
| | - Isabelle Colliot
- AP-HP, CHU Bicêtre, Service de Génétique Moléculaire, Pharmacogénétique et Hormonologie, Le Kremlin-Bicêtre, France
| | - Severine Trabado
- INSERM U 693, Université Paris-Sud, Faculté de Médecine Paris-Sud, Le Kremlin-Bicêtre, France; AP-HP, CHU Bicêtre, Service de Génétique Moléculaire, Pharmacogénétique et Hormonologie, Le Kremlin-Bicêtre, France
| | - Guillaume Bronsard
- Maison Départementale de l'Adolescent et Centre Médico-Psycho-Pédagogique, Conseil Général des Bouches-du-Rhône, France; Laboratoire de Santé Publique EA3279, Faculté de Médecine de Marseille, France
| | - Nathalie Coulon
- Laboratoire Psychologie de la Perception, Université Paris Descartes, CNRS UMR 8158, Paris, France
| | - Michel Botbol
- Service Hospitalo-Universitaire de Psychiatrie de l'Enfant et de l'Adolescent de Brest, EA4686, UBO, Brest, France
| | - Henriette Charbuy
- Medical Biochemistry and Molecular Biology, Paris 6 School of Medicine, Paris, France
| | | | - Yvan Touitou
- Chronobiology Unit, Rothschild Foundation, Paris, France
| |
Collapse
|
14
|
Sarfati J, Trabado S, Rocher L, Mallet D, Betari-Tabet B, Morel Y, Young J. REMOVAL: Pelvic MRI in a 17-year-old XY girl with 5-alpha reductase deficiency and a homozygous Gly115Asp mutation in SRD5A2. Ann Endocrinol (Paris) 2011; 72:310-313. [PMID: 21835392 DOI: 10.1016/j.ando.2011.07.001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/04/2011] [Accepted: 07/04/2011] [Indexed: 11/29/2022]
Abstract
This article has been removed: please see Elsevier Policy on Article Withdrawal (http://www.elsevier.com/locate/withdrawalpolicy).
This article has been removed at the request of the Editor-in-chief and the corresponding author for legal reasons regarding the patient consent.
Collapse
Affiliation(s)
- J Sarfati
- UMR-S693 (ST, SBT, JY), faculté de médecine Paris-Sud, université Paris-Sud, 94276 Le-Kremlin-Bicêtre, France; Service d'endocrinologie et des maladies de la reproduction, hôpital de Bicêtre, Assistance publique-Hôpitaux de Paris, 94275 Le-Kremlin-Bicêtre, France; Laboratoire de génétique moléculaire, pharmacogénétique et hormonologie, 94275 Le-Kremlin-Bicêtre, France; Inserm U693, IFR93, 78, rue du Général-Leclerc, 94275 Le-Kremlin-Bicêtre, France
| | - S Trabado
- UMR-S693 (ST, SBT, JY), faculté de médecine Paris-Sud, université Paris-Sud, 94276 Le-Kremlin-Bicêtre, France; Laboratoire de génétique moléculaire, pharmacogénétique et hormonologie, 94275 Le-Kremlin-Bicêtre, France; Inserm U693, IFR93, 78, rue du Général-Leclerc, 94275 Le-Kremlin-Bicêtre, France
| | - L Rocher
- Service de radiologie, CHU de Bicêtre, 94276 Le-Kremlin-Bicêtre, France
| | - D Mallet
- Laboratoire d'endocrinologie moléculaire et maladies rares, centre de biologie et de pathologie Est, 69677 Bron, France
| | - B Betari-Tabet
- Service d'endocrinologie et des maladies de la reproduction, hôpital de Bicêtre, Assistance publique-Hôpitaux de Paris, 94275 Le-Kremlin-Bicêtre, France
| | - Y Morel
- Laboratoire d'endocrinologie moléculaire et maladies rares, centre de biologie et de pathologie Est, 69677 Bron, France
| | - J Young
- UMR-S693 (ST, SBT, JY), faculté de médecine Paris-Sud, université Paris-Sud, 94276 Le-Kremlin-Bicêtre, France; Service d'endocrinologie et des maladies de la reproduction, hôpital de Bicêtre, Assistance publique-Hôpitaux de Paris, 94275 Le-Kremlin-Bicêtre, France; Inserm U693, IFR93, 78, rue du Général-Leclerc, 94275 Le-Kremlin-Bicêtre, France.
| |
Collapse
|
15
|
Bry-Gauillard H, Trabado S, Bouligand J, Sarfati J, Francou B, Salenave S, Chanson P, Brailly-Tabard S, Guiochon-Mantel A, Young J. Congenital hypogonadotropic hypogonadism in females: Clinical spectrum, evaluation and genetics. Annales d'Endocrinologie 2010; 71:158-62. [DOI: 10.1016/j.ando.2010.02.024] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/15/2010] [Revised: 02/17/2010] [Accepted: 02/17/2010] [Indexed: 12/27/2022]
|
16
|
Trabado S, Nguyen Van Binh P, Martin C, Lafarge-Frayssinet C, Thevenin M, Baudouin F, Warnet JM, Duc HT. Modulated expression of cell surface molecules and in vivo outgrowth of modified melanoma cells. Biomed Pharmacother 2006; 60:693-7. [PMID: 17071049 DOI: 10.1016/j.biopha.2006.09.009] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2006] [Accepted: 09/18/2006] [Indexed: 10/24/2022] Open
Abstract
Modulation of cell surface molecules involved in immune recognition and cellular interactions (class I major histocompatibility complex or MHC-I, B7.1 or CD80, integrin alpha4 or CD49d, tetraspanins CD9, CD81) was examined in modified B16 melanoma cells displaying either inhibited IGF-I expression or transfected OVA encoding gene. It was shown that inhibiting IGF-I expression or inserting OVA encoding gene did not lead to modification relevant to the presence of MHC-I or B7.1. However downregulation of tetraspanin CD9 was observed in modified IGF-I but not in OVA encoding gene inserted melanoma cells. Expression of tetraspanin CD81 and integrin alpha4/CD49d remained unchanged. Inoculated into syngeneic recipients, the modified melanoma cells exhibited significant delayed outgrowth with a reduction in the percentage of lethal tumors observed essentially in hosts injected with inhibited IGF-I expression cells.
Collapse
MESH Headings
- Animals
- Anti-Bacterial Agents/pharmacology
- Antigens, CD/genetics
- Antigens, CD/metabolism
- Antigens, Surface/genetics
- Antigens, Surface/metabolism
- B7-1 Antigen/genetics
- B7-1 Antigen/metabolism
- Cell Line, Tumor
- Cell Survival/drug effects
- DNA, Antisense/genetics
- Down-Regulation/drug effects
- Electroporation/methods
- Female
- Flow Cytometry
- Gene Expression/drug effects
- Histocompatibility Antigens Class I/genetics
- Histocompatibility Antigens Class I/metabolism
- Hygromycin B/pharmacology
- Immunohistochemistry
- Insulin-Like Growth Factor I/genetics
- Insulin-Like Growth Factor I/metabolism
- Integrin alpha4/genetics
- Integrin alpha4/metabolism
- Melanoma, Experimental/genetics
- Melanoma, Experimental/metabolism
- Melanoma, Experimental/pathology
- Membrane Glycoproteins/genetics
- Membrane Glycoproteins/metabolism
- Mice
- Mice, Inbred C57BL
- Ovalbumin/genetics
- Ovalbumin/metabolism
- Tetraspanin 28
- Tetraspanin 29
- Transfection/methods
Collapse
Affiliation(s)
- S Trabado
- Laboratoire de Toxicologie, Faculté de Pharmacie, Université René-Descartes Paris-V, Paris, France
| | | | | | | | | | | | | | | |
Collapse
|
17
|
Rat P, Trabado S, Loddo A, Warnet J. 325 Gestion du risque prion et problèmes de désinfection des dispositifs médicaux en ophtalmologie : rôle du type d’acide peracétique. J Fr Ophtalmol 2005. [DOI: 10.1016/s0181-5512(05)74722-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|